Syntrix Biosystems, Inc. Product Pipeline Review - 2015

1
Syntrix Biosystems, Inc. Product Pipeline Review
- 2015
Published on October - 2015
2
.
Report Overview
About Syntrix Biosystems, Inc. Product Pipeline
Review 2015 Global Markets Directs, Syntrix
Biosystems, Inc. Product Pipeline Review - 2015,
provides an overview of the Syntrix Biosystems,
Inc.s pharmaceutical research and development
focus. This report provides comprehensive
information on the current therapeutic
developmental pipeline of Syntrix Biosystems,
Inc.s, complete with comparative analysis at
various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of
administration (RoA) and molecule type. It also
reviews latest updates, and featured news and
press releases, along with special features on
late-stage and discontinued projects. Global
Markets Directs report features investigational
drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is
built using data and information sourced from
Global Markets Directs proprietary data bases,
Company/University websites, SEC filings,
investor presentations and featured press
releases from company/university sites and
industry-specific third party sources, put
together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/synt
rix-biosystems-inc-product-pipeline-review-2015-ma
rket
3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Syntrix Biosystems, Inc.
including business description, key information
and facts, and its locations and subsidiaries The
report reviews current pipeline of Syntrix
Biosystems, Inc. s human therapeutic division and
enlists all their major and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Syntrix Biosystems, Inc. spipeline
products   Reasons to buy Evaluate Syntrix
Biosystems, Inc. sstrategic position with total
access to detailed information on its product
pipeline Assess the growth potential of Syntrix
Biosystems, Inc. in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the Syntrix Biosystems, Inc. s RD
portfolio and develop key strategic initiatives
to reinforce pipeline in those areas Exploit
in-licensing opportunities by identifying windows
of opportunity to fill portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of Syntrix Biosystems, Inc. and
  exploit collaboration and partnership
  opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of
  Syntrix Biosystems, Inc.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Syntrix Biosystems, Inc. and identify potential
  opportunities in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4List of Figures 4Syntrix
Biosystems, Inc. Snapshot 5Syntrix Biosystems,
Inc. Overview 5Key Information 5Key Facts
5Syntrix Biosystems, Inc. - Research and
Development Overview 6Key Therapeutic Areas
6Syntrix Biosystems, Inc. - Pipeline Review
8Pipeline Products by Stage of Development
8Pipeline Products - Monotherapy 9Syntrix
Biosystems, Inc. - Pipeline Products Glance
10Syntrix Biosystems, Inc. - Late Stage Pipeline
Products 10Phase III Products/Combination
Treatment Modalities 10
7
Table Of Contents
Syntrix Biosystems, Inc. - Clinical Stage
Pipeline Products 11Phase II Products/Combination
Treatment Modalities 11Phase I
Products/Combination Treatment Modalities
12 Syntrix Biosystems, Inc. - Early Stage
Pipeline Products 13Preclinical
Products/Combination Treatment Modalities
13Syntrix Biosystems, Inc. - Drug Profiles
14MGN-1703 14Product Description 14Mechanism
of Action 14RD Progress 14MGN-1601 18Product
Description 18Mechanism of Action 18RD
Progress 18
8
Table Of Contents
MGN-1404 20 Product Description 20Mechanism of
Action 20RD Progress 20MGN-1331 21Product
Description 21Mechanism of Action 21RD
Progress 21MGN-1333 22  Enquiry about this
report _at_ http//www.researchbeam.com/syntrix-biosy
stems-inc-product-pipeline-review-2015-market/enqu
ire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/syntrix-biosystems-inc
-product-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com